Odyssey Health closes exclusive global distribution deal for BreastCheck non-invasive breast test

Odyssey Health, Inc.

Closed sub-license with NeuRX Health granting subsidiary Odyssey Medical Devices exclusive worldwide marketing and distribution rights for BreastCheck.
BreastCheck is a non-invasive, 15-minute test for breast abnormalities, registered with FDA, EU, and UK regulators.
Global breast cancer screening market estimated at $26B; commercial sales expected to begin in H2 2026.
CEO Michael Redmond says agreement provides clear pathway to near-term revenue and supports growth strategy.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Odyssey Health, Inc. entered into Master Technology and Sub-license Agreement with NeuRX Health, Inc. (effective 2025-10-14).

Action: entry
Agreement: license
Counterparty: NeuRX Health, Inc.
Effective: 2025-10-14

Exact text from the filing

On April 21, 2026, Odyssey Health, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) successfully closed the Master Technology and Sub-license Agreement (the “ Agreement ”) with NeuRX Health, Inc. (“ NeuRX ”) which was entered into on October 14, 2025

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Odyssey Health, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-003205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.